

Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein Catalog No: DRA31

Description Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein is produced by our *E.coli* expression

system and the target gene encoding Met1-Ala419 is expressed with a 6His tag at the N-terminus.

Source E.coli

Alternative Name 2019-nCoV coronavirus NP Protein; 2019-nCoV np Protein; 2019-nCoV novel coronavirus

Nucleoprotein Protein

Accession QHD43423.2

Predicted
Molecular Weight

Molecular Weight

49.4kDa

AP

Molecular Weight 50-60kDa under reducing condition

Quality Control Purity: Greater than 95% as determined by reducing SDS-PAGE.

Formulation Supplied as a 0.2 µM filtered solution of 20 mM Tris-HCl, 300 mM NaCl, 1mM EDTA, pH 8.0

Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. Please aliquot the solution

to minimize freeze-thaw cycles. It is not recommended to dilute a concentration less than 100 µg/ml.

Shipping The product is shipped on dry ice pack

Storage Reconstituted protein solution should be stored at ≤ -20°C


Application Immunogen, calibrator or standard.

Background Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity

that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Because of the conservation of N protein sequence


and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.

SDS-PAGE



Purity: Greater than 95% as determined by reducing SDS-PAGE

Bioactivity




Immobilized SARS-CoV-2 (2019-nCoV) NP Antibody (6G9)(Cat#DA027) at 5μ g/ml (100 μ l/well) showing the binding to SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein-His (Cat#DRA31).

The ED50 of SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein-His (Cat#DRA31) is 68 ng/ml.





Batch Stability



Batch stability is confirmed by binding ability with and-2019-nCoV NP Antibody(6G9)(Cat#DA027).

The result showed that the batch variation is no significant differences among these samples.

